Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...
Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
Biotech‑focused Metsera (NASDAQ: MTSR) announced that Novo Nordisk (NYSE: NVO) has submitted a “superior” acquisition...
Roche Announces a $55 M Partnership with Manifold Bio to Build BBB Shuttles
Swiss‑listed pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) confirmed a strategic alliance with platform biotech...
Eli Lilly Announces Phase 3 ATTAIN‑PAD Trial for Oral GLP‑1 Agent orforglipron
Eli Lilly (NYSE: LLY), a global biopharma titan, will commence the ATTAIN‑PAD phase 3 study—an ambitious,...
Green Valley Faces Bribery Fine as Re‑registration Deadline Passes
The Shanghai Pudong New Area Market Supervision Administration issued an administrative penalty against Green Valley...
CARsgen Therapeutics Shares Promising Early Results for Allogeneic CAR‑T Products
China‑based CARsgen Therapeutics Holdings Limited (HKG: 2171) unveiled clinical data for two allogeneic CAR‑T candidates...
Guangzhou’s 12‑Step Plan to Accelerate Innovative Drug and Device Adoption
The Guangzhou Municipal Health Commission issued a comprehensive notice detailing twelve strategic measures aimed at...
Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...
CStone Receives NMPA Approval for CS2009 Phase II Trial in Advanced Solid Tumors
China‑based CStone Pharmaceuticals (HKG: 2616), announced today that the China National Medical Products Administration (NMPA)...
NHSA Re‑designs Drug‑Prescribing Surveillance, Targeting Illicit Use and Resale
The National Healthcare Security Administration issued a comprehensive notice to strengthen the intelligent monitoring of...
Amoy Diagnostics Announce NMPA Approval of China’s First KRAS G12C Companion Diagnostic
Amoy Diagnostics Co., Ltd. (“AmoyDx”) have secured approval from the China National Medical Products Administration...
GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa
China‑based GenAns Biotechnology Co., Ltd. announced that its proprietary gene‑therapy drug GA001 injection received Fast‑Track...
Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting
China‑based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines—olverembatinib (HQP1351), a first‑in‑China...
Sanyou Biopharmaceuticals and Liferiver Bio-Tech Forge Automation‑Driven Alliance to Accelerate Biologic Development
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai Liferiver Bio-Tech Co., Ltd. (SHA: 688317) inked a...
Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital
Yangzi State‑Owned Investment Group (JSIG) and Singapore‑based Perennial Real Estate Holdings Limited (Perennial Group) signed...
Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...
Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework...
AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges
U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose...
Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025
Astellas Pharma Inc. (TYO: 4503) released its consolidated six‑month results for fiscal year 2025 (1 Apr 2025 – 30 Sep 2025). The...